Hien Pham1, Kristina M Utzschneider, Ian H de Boer. 1. Division of Nephrology and Kidney Research Institute, Department of Medicine, Seattle VA Puget Sound Healthcare System, Washington, USA.
Abstract
PURPOSE OF REVIEW: Insulin resistance is a known complication of end-stage renal disease that also appears to be present in earlier stages of chronic kidney disease (CKD). It is a risk factor for cardiovascular disease and an important potential therapeutic target in this population. Measurement of insulin resistance is reviewed in the context of known pathophysiologic abnormalities in CKD. RECENT FINDINGS: Insulin resistance in CKD is due to a high prevalence of known risk factors (e.g. obesity) and to unique metabolic abnormalities. The site of insulin resistance in CKD is localized to skeletal muscle. Estimates based on fasting insulin concentration may not adequately capture insulin resistance in CKD because they largely reflect hepatic defects and because CKD impairs insulin catabolism. A variety of dynamic tests are available to directly measure insulin-mediated glucose uptake. SUMMARY: Insulin resistance may be an important therapeutic target in CKD. Complementary methods are available to assess insulin resistance, and each method has unique advantages, disadvantages, and levels of complexity. These characteristics, and the likelihood that CKD alters the performance of some insulin resistance measurements, must be considered when designing and interpreting clinical studies.
PURPOSE OF REVIEW: Insulin resistance is a known complication of end-stage renal disease that also appears to be present in earlier stages of chronic kidney disease (CKD). It is a risk factor for cardiovascular disease and an important potential therapeutic target in this population. Measurement of insulin resistance is reviewed in the context of known pathophysiologic abnormalities in CKD. RECENT FINDINGS:Insulin resistance in CKD is due to a high prevalence of known risk factors (e.g. obesity) and to unique metabolic abnormalities. The site of insulin resistance in CKD is localized to skeletal muscle. Estimates based on fasting insulin concentration may not adequately capture insulin resistance in CKD because they largely reflect hepatic defects and because CKD impairs insulin catabolism. A variety of dynamic tests are available to directly measure insulin-mediated glucose uptake. SUMMARY:Insulin resistance may be an important therapeutic target in CKD. Complementary methods are available to assess insulin resistance, and each method has unique advantages, disadvantages, and levels of complexity. These characteristics, and the likelihood that CKD alters the performance of some insulin resistance measurements, must be considered when designing and interpreting clinical studies.
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Elisabet Nerpin; Ulf Risérus; Erik Ingelsson; Johan Sundström; Magnus Jobs; Anders Larsson; Samar Basu; Johan Arnlöv Journal: Diabetes Care Date: 2008-05-28 Impact factor: 19.112
Authors: Hien Pham; Cassianne Robinson-Cohen; Mary L Biggs; Joachim H Ix; Kenneth J Mukamal; Linda F Fried; Bryan Kestenbaum; David S Siscovick; Ian H de Boer Journal: Clin J Am Soc Nephrol Date: 2012-03-01 Impact factor: 8.237
Authors: Iram Ahmad; Leila R Zelnick; Nicole R Robinson; Adriana M Hung; Bryan Kestenbaum; Kristina M Utzschneider; Steven E Kahn; Ian H de Boer Journal: Am J Physiol Endocrinol Metab Date: 2017-01-10 Impact factor: 4.310
Authors: Maria P Martinez Cantarin; Scott W Keith; Zhao Lin; Cataldo Doria; Adam M Frank; Warren R Maley; Carlo Ramirez; Costas D Lallas; Ashesh Shah; Scott A Waldman; Bonita Falkner Journal: Cardiorenal Med Date: 2016-05-18 Impact factor: 2.041
Authors: Hong Xu; Xiaoyan Huang; Johan Arnlöv; Tommy Cederholm; Peter Stenvinkel; Bengt Lindholm; Ulf Risérus; Juan Jesús Carrero Journal: Clin J Am Soc Nephrol Date: 2014-01-16 Impact factor: 8.237
Authors: Halil O Ikizler; Leila Zelnick; John Ruzinski; Laura Curtin; Kristina M Utzschneider; Bryan Kestenbaum; Jonathan Himmelfarb; Ian H de Boer Journal: J Ren Nutr Date: 2015-10-23 Impact factor: 3.655
Authors: Ian H de Boer; Leila Zelnick; Maryam Afkarian; Ernest Ayers; Laura Curtin; Jonathan Himmelfarb; T Alp Ikizler; Steven E Kahn; Bryan Kestenbaum; Kristina Utzschneider Journal: J Am Soc Nephrol Date: 2016-01-28 Impact factor: 10.121
Authors: Rodolfo J Galindo; Roy W Beck; Maria F Scioscia; Guillermo E Umpierrez; Katherine R Tuttle Journal: Endocr Rev Date: 2020-10-01 Impact factor: 19.871
Authors: Stanisław Niemczyk; Katarzyna Szamotulska; Kinga Giers; Mariusz Jasik; Zbigniew Bartoszewicz; Katarzyna Romejko-Ciepielewska; Ewa Paklerska; Małgorzata Gomółka; Joanna Matuszkiewicz-Rowińska Journal: Med Sci Monit Date: 2013-07-19